The main objective of the study is to compare the effectiveness of moxifloxacin triple therapy with levofloxacin-based sequential therapy in terms of eradication rate, safety, and patient compliance.
Patients who were confirmed to be positive for Helicobacter Pylori infection were randomly assigned to the eradication treatments. At four weeks after completion of eradication therapy, H. pylori tests were performed with a Stool antigen test.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
162
The eradication rate of H. Pylori with levofloxacin-based sequential therapy
The eradication rate of H. Pylori with moxifloxacin-based triple therapy
Jamal Noor Hospital, Karachi
Karachi, Sindh, Pakistan
Helicobacter pylori status one month after treatment.
Helicobacter pylori status (positive or negative), will be measured by stool test, one month after finishing with therapy.
Time frame: One month after finishing with therapy.
Compliance of patients in both therapy groups in treatment of Helicobacter pylori infection.
Compliance will be measured by counting pills that were taken during therapy. More than or equal 80 % of taken pills will be consider as good compliance
Time frame: One month after finishing with therapy.
Adverse effects of therapy in both groups in treatment of Helicobacter pylori infection.
Patients will be asked to report any adverse effect that occurred during treatment. They will be divided into groups according to the degree of limiting daily activities: no adverse effects; mild (no limit of activities); moderate (partially limited activities); severe (completely limited activities).
Time frame: One month after finishing with therapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.